# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Robbie Marcus maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from $1...
Piper Sandler analyst Adam Maeder maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from ...
Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0...
TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid arter...
Argus Research analyst Steve Silver upgrades Silk Road Medical (NASDAQ:SILK) from Hold to Buy and announces $24 price target.